Zusammenfassung
Ist es für die erfolgreiche Therapie einer malignen Neoplasie im Sinne einer dauerhaften Remission oder Heilung erforderlich, alle Tumorzellen zu eradizieren? Oder genügt es, die Tumorzelllast so weit zu reduzieren, dass das Immunsystem die restlichen Tumorzellen eliminieren oder zumindest langfristig unter Kontrolle halten kann? Spielt die Kinetik der Tumorzellreduktion unter Therapie eine prognostische Rolle? Bestehen Unterschiede zwischen verschiedenen malignen Erkrankungen hinsichtlich der prognos tischen Bedeutung einer unvollständigen Eradikation der Tumorzellen? Gibt es eine kritische residuelle Tumorzellmenge, die als prognostischer Parameter herangezogen werden kann? Wie in diesem Kapitel dargelegt, können diese und andere Fragen durch die Überwachung der so genannten minimalen Resterkrankung beantwortet werden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bader P, Hancock J, Kreyenberg H et al (2002) Minimal residual di sease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16: 1668–1672
Cave, H, van der Werff ten Bosch J, Suciu, S et al for the EORTC (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 339:591–598
Coustan-Smith E, Behm FG., Sanchez J et al (1998) Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351:550–554
Coustan-Smith E, Sancho J, Hancock ML et al (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691–2696
De Haas V, Breunis WB, Dee R et al (2002) The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukemia. Br J Haematol 116:87–93
Dworzak MN, Panzer-Grümayer ER (2003) Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia and Lymphoma 44:1445–1455
Dworzak MN, Fritsch G, Fleischer C et al (1998) Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol 26:305–313
Dworzak MN, Stolz F, Froschl G et al (1999) Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping:a study of five cases controlled by genetic methods. Exp Hematol 27:673–681
Dworzak MN, Fröschl G, Printz D et al for the Austrian BFM Study Group (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99:1952–1958
Eckert C, Biondi A, Seeger K et al (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukemia. Lancet 358:1239–41
Hehlmann R, Hochhaus A, Berger U, Reiter A (2000) Current trends in the management of chronic myelogenous leukemia. Ann Hematol 79:345–354
Horibe K, Fukuda M, Miyajima Y et al (2001) Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 36:203–4
Kiyoi H, Naoe T, Nakano Y et al (1999) Prognostic implication of FLT3 and N-RAS mutations in acute myeloid leukemia. Blood 93:3074–3080
Knechtli CJ, Goulden NJ, Hancock JP et al (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92:4072–4079
Knudson AJ (1971) Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820–827
Lion T, Henn T, Gaiger A et al (1993) Early detection of impending relapse by quantitative polymerase-chain reaction in patients with chronic myelogenous leukemia after bone marrow transplantation. Lancet 341:275–276
Lion T (1994) Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukaemia. The European Investigators on chronic myelogenous leukemia group. Bone Marrow Transplant 14:505–509
Lion T (1996) Monitorino of residual disease in chronic myelogenous leucemia: methodological approaches and clinical aspects. Leukemia 10:896–906
Lion T (1999) Minimal residual disease. Curr Opin Hematol 6:406–411
Marcucci G, Livak KJ, Bi W et al (1998) Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction. Leukemia 12: 1482–89
Mehes G, Luegmayer A, Hattinger CM et al (2001) Automatic detection and genetic profiling of disseminated neuroblastoma cells. Med Pediatr Oncol 36:205–209
Meshinchi S, Woods WG, Stirewalt DL et al (2001) Prevalence and prognostic significance of flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97:89–94
Neale GAM, Coustan-Smith E, Pan Q et al (1999) Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 13: 1221–1226
Nyvold C, Madsen HO, Ryder LP et al (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99:1253–1258
San Miguel JF, Vidriales MB, Lopez-Berges C et al (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukaemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746–1751
Schleiermacher G, Peter M, Oberlin O et al (2003) Increased risk of systemic relapses associated with bone marrow metastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 21:85–91
Szczepanski T, Flohr T, van der Velden VHJ et al (2002) Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15:37–57
Uzunel M, Mattson J, Jaksch M et al (2001) The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 98:1982–1984
van Dongen JJM, Seriu T, Panzer-Gruemayer ER et al (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731–1738
Verhagen OJHM, Willemse MJ, Breunis WB et al (2000) Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14:1426–1435
Viehmann S, Teigler-Schlegel A, Bruch J et al (2003) Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 17:1130–1136
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Lion, T., Dworzak, M. (2006). Minimale Resterkrankung. In: Gadner, H., Gaedicke, G., Niemeyer, C., Ritter, J. (eds) Pädiatrische Hämatologie und Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29036-2_47
Download citation
DOI: https://doi.org/10.1007/3-540-29036-2_47
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-03702-6
Online ISBN: 978-3-540-29036-0
eBook Packages: Medicine (German Language)